Medicaid GLP-1 coverage in Arkansas, 2026.
What Arkansas Medicaid actually covers for Wegovy, Zepbound, Ozempic and Mounjaro. Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization. Here is the current 2026 reality for Arkansas.
Coverage summary
| Indication | Coverage |
|---|---|
| Wegovy (weight loss) | No |
| Zepbound (weight loss) | No |
| Ozempic / Mounjaro (type 2 diabetes) | Yes |
| Compounded semaglutide / tirzepatide | No |
Prior-authorization criteria
| Criterion | Value |
|---|---|
| PA burden | Medium |
| BMI threshold (weight-loss path) | Not applicable (weight-loss path not covered) |
| Comorbidity required | No |
| Last PDL update reviewed | 2025-Q3 |
What this means in practice
Arkansas Medicaid is primarily fee-for-service with a PASSE program for high-need populations. The state PDL excludes weight-loss medications. T2D coverage requires PA with documented A1c.
Managed-care organizations in Arkansas
Arkansas Medicaid operates primarily as fee-for-service. PA submissions go directly to the state Medicaid pharmacy benefit administrator rather than to a contracted MCO.
Cash-pay alternatives if Medicaid does not cover you
Cash-pay compounded GLP-1 or manufacturer patient-assistance are the practical fallback. See /learn/glp1-patient-assistance-programs/.
For ranked cash-pay options, see programs ranked by price and programs under $150 a month. For manufacturer patient-assistance routes that bypass insurance entirely, see every cost-reduction pathway in 2026.
Take it to your prescriber: PA letter library
If you qualify under one of the covered indications above, the prior-authorization route is the cheapest path. We maintain a PA letter library with templates for Aetna, Cigna, UnitedHealthcare, Anthem BCBS, Kaiser, Humana, Tricare, FEHB and Medicare Advantage, cross-indexed against six qualifying clinical pictures. Each template cites the plan's policy document, the qualifying ICD-10 codes and the registration-trial evidence.
If you have type 2 diabetes plus chronic kidney disease and established cardiovascular disease, the triple-indication evidence stack (FLOW + SELECT + SUSTAIN-6) is the strongest PA path in any state.
Other state Medicaid pages
See the full 51-state coverage table for the side-by-side view across every US state.
How we built this page
Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.
Last updated: 2026-05-23. We re-verify quarterly by checking each state Medicaid PDL and PA criteria. If you have recently had a different experience with Arkansas Medicaid, email hello@glpchart.com with the details and we will re-verify.
